NCT05220358View on ClinicalTrials.gov

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

February 13, 2026

Study Completion Date

February 13, 2026

Conditions
HIV-1-infection
Interventions
DRUG

Fostemsavir 600 MG [Rukobia]

FTR 600 mg PO BID added to daily suppressive HIV regimen

Trial Locations (1)

32803

Orlando Immunology Center, Orlando

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Orlando Immunology Center

OTHER

NCT05220358 - Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study | Biotech Hunter | Biotech Hunter